$EVO News
Last published 6d ago
- 6d agoEVOQuarterly Statement 9M 2026 - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon and welcome to today's webcast and conference call. My name is Sarah Harkin and I'm the Head of Corporate Communications and Investor Relations at Evotech. Please allow me to introduce today'
- 6d agoEVOQuarterly Statement 9M 2026 - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon and welcome to today's webcast and conference call. My name is Sarah Harkin and I'm the Head of Corporate Communications and Investor Relations at Evotech. Please allow me to introduce today'
- 2w agoEVTvEVOEvotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026PR NewswireHAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide
- 4w agoEVTvEVOEvotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardPR NewswireWill lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovationBrings more than 25 years of global experience in
- 1mo agoEVOEvotec Announces Chief Scientific Officer TransitionPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down...
- 1mo agoEVOEvotec SE - 1773601 - EVOTEC SEEarnings Call TranscriptsHi, everyone. Thanks for coming here. I'm Giovanni Zerilla, Executive Director in the Healthcare Investment Banking team at Morgan Stanley, and I'm here with Claire Ainshaw-Wood, who is CFO at Evotech. Hi, Claire. Thanks
- 2mo agoEVOJust - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical StudiesPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of...
- 2mo agoEVOEvotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid TumorsPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel...
- 3mo agoEVOODTXEvotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory DiseasesPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics,...
- 3mo agoEVOAnnual Report 2025 - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at Evotech. Please allow me to introduce today's
- 3mo agoEVOEvotec SE - Annual Report 2025 - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at Evotech. Please allow me to introduce today's
- 3mo agoNAGEEVONiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168Business WireCollaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development expertise,
- 3mo agoNAVNEVOEvotec Selects Navan to Unify Global Travel, Payments, and Expense ManagementBusiness WireGlobal drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ:NAVN), the global AI-powered business travel and expense platform, today announced
- 4mo agoEVOPreliminary Second Quarter and First Half 2026 Results and Update Full-Year 2026 Outlook - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Fahki and I'm the Head of Global Communications and Investor Relations at Evotech. Please allow me to introduce today's s
- 4mo agoEVOEvotec SE - Preliminary Second Quarter and First Half 2026 Results and Update Full-Year 2026 Outlook - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Fahki and I'm the Head of Global Communications and Investor Relations at Evotech. Please allow me to introduce today's s
- 4mo agoEVOAd hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 OutlookPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half ...
- 4mo agoEVOJust - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for BiologicsPR NewswireEvotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new...
- 5mo agoEVOEvotec Reports Results of the Annual General Meeting 2026PR NewswireEvotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting. All agenda items put to vote were...
- 5mo agoEVOEvotec Appoints Rui Wang as Head of Global In Silico and AIACCESS NewswireHAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang
- 6mo agoEVOEvotec SE Successfully Placed €116.1 Million Convertible BondsACCESS NewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE,
- 6mo agoEVOQuarterly Statement 9M 2026 - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon and welcome to today's webcast and conference call. My name is Sarah Harkin and I'm the Head of Corporate Communications and Investor Relations at Evotech. Please allow me to introduce today'
- 6mo agoEVOEvotec First Quarter 2026 Financial Results and Business Update - EvotecEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at EvoTech. Please allow me to introduce today's
- 6mo agoEVOEvotec First Quarter 2026 Financial Results and Business Update - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at EvoTech. Please allow me to introduce today's
- 6mo agoEVOEvotec First Quarter 2026 Financial Results and Business Update - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at EvoTech. Please allow me to introduce today's
- 6mo agoEVOEvotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with AlmirallACCESS NewswireJoint Evotec-Almirall team advances small molecule program to preclinical development significantly outperforming standard industry timelinesCollaboration leverages Evotec's end-to-end integrated AI/ML-driven R&D
- 6mo agoEVOEvotec Receives Grants to Advance Tuberculosis TreatmentACCESS NewswireGrants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testingNew funding from the Gates Foundation extends Evotec's commitment to
- 6mo agoEVOEvotec Announces New Nomination to Board of DirectorsACCESS NewswireNomination of Dr. Wolfgang Hofmann as independent Supervisory Board member to further strengthen oversight and governance capabilitiesConclusion of cooperation agreement with MAK Capital following constructive
- 6mo agoEVOEvotec SE to Announce First Quarter 2026 Results on May 6, 2026ACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 29, 2026 / Evotec SE ) will hold a webcast and conference call to announce its financial results for the first quarter 2026 and provide a
- 6mo agoEVOEvotec Announces Chief Financial Officer TransitionACCESS NewswirePaul Hitchin to step down as of April 30, 2026Claire Hinshelwood appointed to CFO role as of May 1, 2026 HAMBURG, DE / ACCESS Newswire / April 24, 2026 / Evotec SE today
- 7mo agoEVOEvotec Appoints Dr. Ingrid Müller as Chief Operating OfficerACCESS NewswireWill play key role in strengthening cross-functional execution in support of global platform, scientific capabilities and partner delivery as well as the execution of the Horizon initiativeBrings more than 20 years of
- 7mo agoEVOAnnual Report 2025 - Evotec SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at Evotech. Please allow me to introduce today's
- 7mo agoEVOEvotec Nominates Dieter Weinand as Supervisory Board ChairmanACCESS NewswireStrengthens Supervisory Board leadership to support Evotec's transformation, with a focus on commercial execution, strategic partnerships and profitabilityIndustry veteran brings more than 30 years of global
- 7mo agoEVOEvotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026ACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE will hold a webcast and conference call to announce its financial results for the fourth quarter and full-year 2025 and
- 7mo agoEVOEvotec Appoints Dr. Ashiq H. Khan as Chief Commercial OfficerACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 1, 2026 / Evotec SE today announced the appointment of Dr. Ashiq H. Khan as EVP Global Head, Chief Commercial Officer. Dr. Khan brings to
- 7mo agoEVOJust - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related VirusesACCESS NewswireThe program leverages Just - Evotec Biologics' advanced biomanufacturing platform to deliver high-quality, scalable, cost-efficient production through significantly higher yieldsManufacturing process development
- 7mo agoEVOEvotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study InitiationACCESS NewswireDosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancerTransformative moment in strategic protein
- 8mo agoEVOHorizon Analyst Call - EVOTEC SEEarnings Call TranscriptsGood morning, good afternoon, and welcome to today's webcast and conference call. My name is Sarah Farkey, and I'm the Head of Global Communications and Investor Relations at EvoTech. Please allow me to introduce today's
- 11mo agoEVOEvotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport SyndromeACCESS NewswirePhase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon first dosing of first study participant in early 2026 HAMBURG, DE / ACCESS
- 1y agoEVOEvotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation PartnershipACCESS NewswireMilestone payment reflects continued progress under strategic research collaboration addressing high-need patient populationsFDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE /
- 1y agoEVOEvotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025ACCESS NewswireHAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE will announce its interim statement for the first nine months
- 1y agoBMYEVOEvotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers SquibbACCESS NewswireAdvances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE
- 1y agoEVOEvotec SE (EVO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoEVOEvotec SE Reports H1 2025 Results: Strong Progress on Strategy ExecutionACCESS NewswireStrategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductionsReporting segment formerly known as Shared R&D renamed to Discovery & Preclinical
- 1y agoEVOEvotec SE to announce first half-year results 2025 on 13 August 2025ACCESS NewswireHAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE will announce its half-year interim report for the first six
- 1y agoEVOEvotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue MixACCESS NewswireSuccessful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platformsHigh-margin technology license revenues expected to have
- 1y agoEVOEvotec SE Adjusts Revenue Guidance while Confirming Profit GuidanceACCESS NewswireHAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE announces that it has updated its revenue guidance
- 1y agoEVOEvotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney InjuryACCESS NewswireNURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury patients, developed as part of a research consortium led by
- 1y agoEVOEvotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis TreatmentsACCESS NewswireGates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The collaboration continues a successful partnership on evaluating
- 1y agoEVOEvotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market EnvironmentACCESS NewswireGroup revenues of € 200 m, on track towards guidance; Shared R&D with similar trend as 2024; Just - Evotec Biologics with continuing growth momentumStrong progress in strategic protein degradation partnership
- 1y agoEVOEvotec SE to Announce Results for the First Quarter 2025 on 6 May 2025ACCESS NewswireHAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE will announce its interim statement for the first quarter of 2025 on Tuesday, 6 May 2025.The